NCT04344600View on ClinicalTrials.gov

Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection

PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 29, 2020

Primary Completion Date

September 24, 2021

Study Completion Date

September 24, 2021

Conditions
Sars-CoV-2 Infection
Interventions
DRUG

Peginterferon lambda alfa-1a subcutaneous injection

Peginterferon lambda-1a 180 micrograms by subcutaneous injection

OTHER

Saline

Saline subcutaneous injection

Trial Locations (1)

21287

Johns Hopkins Hospital, Baltimore

Sponsors

Collaborators (1)

Eiger BioPharmaceuticals
All Listed Sponsors
collaborator

Eiger BioPharmaceuticals

INDUSTRY

lead

Johns Hopkins University

OTHER

NCT04344600 - Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection | Biotech Hunter | Biotech Hunter